Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs The Coca-Cola Co K (KO) Price & Performance

Charles River Laboratories Intl. IncTrade
The Coca-Cola Co KTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs The Coca-Cola Co K — how do they compare? Charles River Laboratories Intl. Inc trades at $282.01 (market cap $13.22B), while The Coca-Cola Co K trades at $86.46 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 28.3× Charles River Laboratories Intl. Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLKO
Market Cap
$13.22B$373.76B
Sector
HealthConsumer Staples
52-Week High
$282.00$89.08
52-Week Low
$145.57$65.67
Enterprise Value
$16.06B$400.93B
Volume
14,630,257
Dividend Yield
2.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $267.49, up 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.02 versus $2.77 expected, and raised full-year guidance. Despite negative net income margins and high valuation multiples, analyst sentiment remains overwhelmingly positive with 72% buy ratings.

CRL shows operational strength with consistent earnings beats and improved demand, yet faces risks from high debt and profitability challenges. The consensus price target of $277.29 suggests modest upside, but investors must weigh growth prospects against valuation concerns and macroeconomic pressures on biotech spending.

The Coca-Cola Co K

Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.

The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO